Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset ...

Merck & Co on Thursday posted higher third quarter revenue as growth from its blockbuster cancer drug Keytruda offset falling ...

Merck said its narrowed profit guidance reflects several new items, including "lower estimated costs related to the impact of ...

Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on ...

Keytruda remains a major growth driver, with Q2 revenue up 9% year over year, but its looming loss of exclusivity is ...

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...

Merck also lowered revenue guidance for 2025. 10 stocks we like better than Merck › The stock for pharmaceutical giant Merck (NYSE: MRK) was trading down more than 3% Monday morning. That's a big drop ...

As Merck looks for growth opportunities ahead of Keytruda’s tumble over the patent cliff, the company’s future now looks a ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.

Merck & Co (MSD) and Eisai are set to discontinue their Phase III clinical trial for unresectable, non‑metastatic ...